Management updated its full-year guidance by revising revenue expectations downward at constant exchange rates, citing stronger-than-anticipated Vyvanse generic erosion in the U.S. Furuta said Takeda is “revising only revenue guidance to low single-digit decline at CER,” while maintaining full-year guidance for core operating profit and core EPS due to ongoing operating expense discipline. Based on revised FX assumptions, Takeda forecast full-year revenue of JPY 4.53 trillion, core operating profit of JPY 1 ...